The Priority Review

Tag

CRO and CDMO

1 story

  1. Business

    Fresenius gets exclusive access to up to 37 WuXi Biologics biosimilar candidates

    Fresenius said it has exclusive access to up to 37 identified biosimilar candidates from WuXi Biologics over the next decade, and will pay a fee for service for each candidate it selects. Fresenius holds the commercialization rights, and WuXi Biologics' network is expected to run development.